| 8:55-9:00Opening Remark | ||
|---|---|---|
| Dr. Norifumi Kawada (President of APASL STC Osaka) | ||
| 9:00-10:40Session 1: Immunology, Inflammation and Regeneration in Hepato-Biliary Diseases | ||
|---|---|---|
| Dr. Robert F. Schwabe (USA) / Dr. Tawesak Tanwandee (Thailand) | ||
| 09:00-09:20 | S1-1 | “Role of Hepatic Stellate Cells in Liver Cancer” |
| Dr. Robert F Schwabe (USA) | ||
| 09:20-09:40 | S1-2 | “Multiomics Profiling Identifies the Pro-tumoral Immune Networks in the Steatotic Tumor Microenvironment in Non-viral Hepatocellular Carcinoma” |
| Dr. Tetsuo Takehara (Japan) | ||
| 09:40-10:00 | S1-3 | “Inflammasome Modulation to Treat NASH & Liver Fibrosis” |
| Dr. Ariel Feldstein (USA) | ||
| 10:00-10:05 | S1-4 | “Toll-like Receptor (TLR)-3 and TLR-9 Genes Polymorphism with Hepatitis C Virus Specific Cell Immunity Outcomes in Egyptian Health-care Workers” |
| Dr. Mohamed Abdel-Samiee (Egypt)Selected Paper #10061 | ||
| 10:05-10:10 | S1-5 | “The New Immunological Strategy of HCC Prevention to Suppress MICA” Shedding |
| Dr. Jun Arai (Japan)Selected Paper #10060 | ||
| 10:10-10:40 | Discussion Time | |
| 10:50-12:30Session 2: Molecular Basis of Hepatitis B/C Virus Infection and Therapy | ||
|---|---|---|
| Dr. Jin Mo Yang (Korea) / Dr. A. Kadir Dokmeci (Turkey) | ||
| 10:50-11:10 | S2-1 | “Being Involved in Molecular Biology for 40 Years; COVID-19 and HCC” |
| Dr. Masao Omata (Japan) | ||
| 11:10-11:30 | S2-2 | “Viral Quasispecies Diversity and the Outcomes of Chronic Hepatitis B” |
| Dr. Jia-Horng Kao (Taiwan) | ||
| 11:30-11:50 | S2-3 | “Development of New Therapies for CHB-2021 and Beyond” |
| Dr. George Lau (Hong Kong) | ||
| 11:50-11:55 | S2-4 | “A Robust Cell Culture System for Anti-hepatitis B Virus Drug Study via Epigenetic Reprogramming” |
| Dr. Luc Gailhouste (Japan)Selected Paper #10022 | ||
| 11:55-12:00 | S2-5 | “Zinc Chloride Enhances dsRNA-induced beta-interferon Promoter Activity through the Inhibition of Mitogen-Activated Protein Kinase Kinase 3 Expression” |
| Dr. Tatsuo Kanda (Japan)Selected Paper #10064 | ||
| 12:00-12:30 | Discussion Time | |
| 12:40-13:40Luncheon Seminar 1 (Sponsored by Eisai Co. Ltd. / MSD K.K.) | ||
|---|---|---|
| Junji Furuse (Japan) | ||
| 12:40-13:10 | “Consideration of the Decision Process of Treatment in Patients with Hepatocellular Carcinoma” | |
| Dr. Sadahisa Ogasawara (Japan) | ||
| 13:10-13:40 | “Clinical Outcome of Lenvatinib Therapy in Japanese Patients with Unresectable HCC” | |
| Dr. Kaoru Tsuchiya (Japan) | ||
| 13:50-14:20Meet the Expert 1 | ||
|---|---|---|
| “Acute on Chronic Liver Failure” | ||
| Dr. Shiv K Sarin (India) | ||
| 14:30-15:00Meet the Expert 2 | ||
|---|---|---|
| “COVID-19 Vaccination in Chronic Liver Diseases” | ||
| Dr. Xiaolong Qi (China) | ||
| 15:10-16:50Session 3: Genetic and Epigenetic Regulation of Liver Diseases | ||
|---|---|---|
| Dr. Tetsuo Takehara (Japan) / Dr. Derek A. Mann (UK) | ||
| 15:10-15:30 | S3-1 | “Genomic Landscape of Hepatocarcinogenesis” |
| Dr. Tatsuhiro Shibata (Japan) | ||
| 15:30-15:50 | S3-2 | “Epigenetic Changes Caused by Hepatitis C Virus Infection Persist Even after Viral Eradication and Pose a Risk of Hepatocellular Carcinoma” |
| Dr. Kazuaki Chayama (Japan) | ||
| 15:50-16:10 | S3-3 | “Epigenetic Control of Hepatic Stellate Cell Activation and Liver Fibrosis” |
| Dr. Derek A Mann (UK) | ||
| 16:10-16:15 | S3-4 | “COLCA1 and COLCA2, the Effector Genes Driven by rs1944919 in Primary Biliary Cholangitis (PBC) Susceptibility Locus Chromosome 11q23.1 in the Japanese Population” |
| Dr. Yuki Hitomi (Japan)Selected Paper #10002 | ||
| 16:15-16:20 | S3-5 | “Palmitate Disrupts the Circadian Rhythm of Mitochondrial Sirtuins in Non-neoplastic Hepatocytes (PH5CH8), While it Restores the Rhythm in Hepatocellular Carcinoma Cell Line (HepG2)” |
| Dr. Savera Aggarwal (India)Selected Paper #10062 | ||
| 16:20-16:50 | Discussion Time | |
| 15:10-16:50Session 3: Genetic and Epigenetic Regulation of Liver Diseases | ||
|---|---|---|
| Dr. Tetsuo Takehara (Japan) / Dr. Derek A. Mann (UK) | ||
| 15:10-15:30 | S3-1 | “Genomic Landscape of Hepatocarcinogenesis” |
| Dr. Tatsuhiro Shibata (Japan) | ||
| 15:30-15:50 | S3-2 | “Epigenetic Changes Caused by Hepatitis C Virus Infection Persist Even after Viral Eradication and Pose a Risk of Hepatocellular Carcinoma” |
| Dr. Kazuaki Chayama (Japan) | ||
| 15:50-16:10 | S3-3 | “Epigenetic Control of Hepatic Stellate Cell Activation and Liver Fibrosis” |
| Dr. Derek A Mann (UK) | ||
| 16:10-16:15 | S3-4 | “COLCA1 and COLCA2, the Effector Genes Driven by rs1944919 in Primary Biliary Cholangitis (PBC) Susceptibility Locus Chromosome 11q23.1 in the Japanese Population” |
| Dr. Yuki Hitomi (Japan)Selected Paper #10002 | ||
| 16:15-16:20 | S3-5 | “Palmitate Disrupts the Circadian Rhythm of Mitochondrial Sirtuins in Non-neoplastic Hepatocytes (PH5CH8), While it Restores the Rhythm in Hepatocellular Carcinoma Cell Line (HepG2)” |
| Dr. Savera Aggarwal (India)Selected Paper #10062 | ||
| 16:20-16:50 | Discussion Time | |
| 17:00-18:40Session 4: Molecular Basis of Liver Fibrosis and Cirrhosis Therapy | ||
|---|---|---|
| Dr. Jordi Gracia-Sancho (Spain) / Dr. Xiaolong Qi (China) / Dr. Kazuo Ikeda (Japan) | ||
| 17:00-17:20 | S4-1 | “Treatment Strategy for Liver Fibrosis Based on Deactivation of Fibrogenic Hepatic Stellate Cells” |
| Dr. Yutaka Inagaki (Japan) | ||
| 17:20-17:40 | S4-2 | “Molecular Basis of Portal Hypertension Therapy” |
| Dr. Jordi Gracia-Sancho (Spain) | ||
| 17:40-18:00 | S4-3 | “The Role of Human Extracellular Matrix in Driving Tissue Fibrosis and Cirrhosis” |
| Dr. Giuseppe Mazza (UK) | ||
| 18:00-18:05 | S4-4 | “Behavior of Reactive Cholangiocytes in the Tissue Repair Stage from Chronic Liver Injury” |
| Dr. Yasuhiro Nakano (Japan)Selected Paper #10029 | ||
| 18:05-18:10 | S4-5 | “Capacity of Extracellular Globins in Suppression of Collagen Production from Activated Hepatic Stellate Cells via Scavenging ROS and Promoting MMP-1 Secretion” |
| Dr. Vu Ngoc Hieu (Japan)Selected Paper #10037 | ||
| 18:10-18:40 | Discussion Time | |
| 18:50-19:50Evening Seminar 1:Sponsored by Chugai Pharmaceutical Co., Ltd. | ||
|---|---|---|
| Dr. Kiyoshi Hasegawa (Japan) | ||
| “A New Era of Cancer Immunotherapy in Hepatocellular Carcinoma” | ||
| Dr. Masatoshi Kudo (Japan) | ||
| 8:00-9:00Morning Seminar: Sponsored by Otsuka Pharmaceutical Co., Ltd. | ||
|---|---|---|
| Dr. Hitoshi Yoshiji (Japan) | ||
| “Management of Liver Cirrhosis: Summary of JSGE & JSH Evidence-based Clinical Practice Guidelines for Liver Cirrhosis 2020” | ||
| Dr. Naoya kato (Japan) | ||
| 9:10-11:10Session 5: Molecular Basis of Alcoholic and Nonalcoholic Steatohepatitis and Therapy | ||
|---|---|---|
| Dr. Gyongi Szabo (USA) / Dr. Ekihiro Seki (USA) / Dr. Kenichi Ikejima (Japan) | ||
| 9:10-9:30 | S5-1 | “Inflammasome Activation and microRNAs are Molecular Drivers and Therapeutic Targets in Steatohepatitis” |
| Dr. Gyongi Szabo (USA) | ||
| 9:30-9:50 | S5-2 | “Treatment Targets for Nonalcoholic Steatohepatitis” |
| Dr. Vincent Wong (Hong Kong) | ||
| 9:50-10:10 | S5-3 | “New Therapeutic Strategy for Alcoholic Liver Disease: Role of TLR7 and IL- 22” |
| Dr. Ekihiro Seki (USA) | ||
| 10:10-10:30 | S5-4 | “Molecular Basis of Alcoholic and Metabolic Steatohepatitis and Therapy” |
| Dr. Jacob George (Australia) | ||
| 10:30-10:35 | S5-5 | “Possible Repurposing of the Analgesic Neurotropin for NAFLD/NASH Treatment” |
| Dr. Takashi Tsuchiya (USA)Selected Paper #10014 | ||
| 10:35-10:40 | S5-6 | “Gut-liver Axis-mediated Mechanism of NASH-associated Hepatocellular Carcinoma Progression” |
| Dr. Ryota Yamagishi (Japan)Selected Paper #10042 | ||
| 10:40-11:10 | Discussion Time | |
| 11:20-13:00Session 6: Use of Pluripotent Stem Cells and Reprogrammed Cells for Therapy | ||
|---|---|---|
| Dr. Atsushi Miyajima (Japan) / Dr. Diana A. Payawal (Philippines) | ||
| 11:20-11:40 | S6-1 | “Generation of Quiescent Hepatic Stellate Cells from Human iPSCs and Development of Anti-fibrotic Drugs” |
| Dr. Atsushi Miyajima (Japan) | ||
| 11:40-12:00 | S6-2 | “Cell Identity Conversion and Liver Regeneration” |
| Dr. Lijian Hui (China) | ||
| 12:00-12:20 | S6-3 | “Generation of Human Liver using iPS Cells for Regenerative Therapies” |
| Dr. Hideki Taniguchi (Japan) | ||
| 12:20-12:25 | S6-4 | “The Therapeutic Effect of Human Placenta Mesenchymal Stem Cell- Derived Exosomes on Primary Sclerosing Cholangitis” |
| Dr. Wenyi Chen (China)Selected Paper #10063 | ||
| 12:25-12:30 | S6-5 | “Kruppel-like Factor 15 Induces the Development of Mature-type Hepatocytes from Progenitor Cells” |
| Dr. Kota Tsuruya (Japan)Selected Paper #10044 | ||
| 12:30-13:00 | Discussion Time | |
| 13:10-14:10Luncheon Seminar 2: Sponsored by AbbVie GK | ||
|---|---|---|
| Tatehiro Kagawa (Japan) | ||
| 13:10-13:40 | “Clinical Outcome of Antiviral Therapy in Patients with Hepatitis C Virus Infection” | |
| Dr. Toshifumi Tada (Japan) | ||
| 13:40-14:10 | “Hepatocellular Carcinoma Developing after the Eradication of Hepatitis C Virus: Surveillance, Characteristics, and Prognosis” | |
| Dr. Hidenori Toyoda (Japan) | ||
| 14:20-16:20Session 7: Gut-Liver-Brain Axis in Hepatic Pathophysiology and Clinical Medicine | ||
|---|---|---|
| Dr. Shiv K Sarin (India) / Dr. Tatiana Kisseleva (USA) | ||
| 14:20-14:40 | S7-1 | “IL-17 Signaling in Steatotic Hepatocytes Promotes Alcoholic Liver Disease- induced Hepatocellular Carcinoma” |
| Dr. Tatiana Kisseleva (USA) | ||
| 14:40-15:00 | S7-2 | “Gut Microbiota and Autoimmune Diseases – Type 1 Diabetes and Multiple Sclerosis –” |
| Dr. Hiroshi Ohno (Japan) | ||
| 15:00-15:20 | S7-3 | “The Liver-brain-gut Neural Reflex Maintains the Niche of Gut Regulatory T Cells” |
| Dr. Takanori Kanai (Japan) | ||
| 15:20-15:40 | S7-4 | “High-throughput Screening of New Compounds that Remove Senescent Cell Toward Prevention of HCC Development” |
| Dr. Eiji Hara (Japan) | ||
| 15:40-15:45 | S7-5 | “Nimbolide Restores Gut Dysbiosis and Prevents Bacterial Translocation by Improving Tight Junction Proteins Expression in an Experimental Hepatocarcinogenesis” |
| Dr. Balasubramaniyan Vairappan (India)Selected Paper #10050 | ||
| 15:45-15:50 | S7-6 | “Dysbiosis of the Gut Microbiota Associated with Plasma Levels of IFN- &gamma and Viral Load in Patients with Acute Hepatitis E Infection” |
| Dr. Jian Wu (China)Selected Paper #10054 | ||
| 15:50-16:20 | Discussion Time | |
| 16:30-18:30Session 8: Diagnosis and Therapy on Hepatic and Biliary Cancer | ||
|---|---|---|
| Dr. Masao Omata (Japan) / Dr. Jia-Horng Kao (Taiwan) | ||
| 16:30-16:50 | S8-1 | “Whole Genomics and Precision Oncology for Hepato-Biliary Cancer” |
| Dr. Hidewaki Nakagawa (Japan) | ||
| 16:50-17:10 | S8-2 | “Biomarkers in the Treatment of Liver Cancer” |
| Dr. Naoya Kato (Japan) | ||
| 17:10-17:30 | S8-3 | “Nobel Treatment Strategy for Intermediate-stage Hepatocellular Carcinoma” |
| Dr. Masatoshi Kudo (Japan) | ||
| 17:30-17:50 | S8-4 | “HCC Surveillance in Patients with Pharmacologically Treated Viral Hepatitis” |
| Dr. Massimo Colombo (Italy) | ||
| 17:50-17:55 | S8-5 | “Analysis of Tumor Microenvironment in Patients with Advanced Hepatocellular Carcinoma Eligible for Systemic Therapy” |
| Dr. Hiroaki Kanzaki (Japan)Selected Paper #10008 | ||
| 17:55-18:00 | S8-6 | “Soluble PD-1 as a Potential Biomarker for Predicting Response to the Immune Checkpoint Inhibitor in HCC Patients” |
| Dr. Yutaka Yasui (Japan)Selected Paper #10027 | ||
| 18:00-18:30 | Discussion Time | |
| 18:40-19:40Evening Seminar 2: Sponsored by Gilead Sciences K.K. | ||
|---|---|---|
| Dr. Yasuhito Tanaka (Japan) | ||
| “Novel Agents for HBV Therapy” | ||
| Dr. Man-Fung Yuen (Hong Kong, China) | ||
| 19:40-19:50Closing Remark | ||
|---|---|---|
| Dr. Norifumi Kawada (President of APASL STC Osaka) | ||
| P-01 | #10028 | “Combination Therapy of Juzentaihoto and Mesenchymal Stem Cells Attenuates Liver Damage and Regresses Fibrosis in Mice” |
|---|---|---|
| Dr. Takahiro Iwasawa (Japan) | ||
| P-02 | #10057 | “The Anti-fibrotic Effect of ex vivo Expanded CD34+Cell Transplantation in a Mouse Model of NASH” |
| Dr. Atsutaka Masuda (Japan) | ||
| P-03 | #10056 | “Cell Membrane-mediated Direct Crosstalks between Hepatocytes and HSCs” |
| Dr. Kirara Inoue (Japan) | ||
| P-04 | #10009 | “Bioinformatics Study of Genes E1 and E2 from Hepatitis C Virus (HCV) with Genotypes 1, 2, 3 and 6 as Vaccine Candidates for Virus-like Particles (VLPs)” |
| Dr. Rifaldy Fajar (Indonesia) | ||
| P-05 | #10052 | “Improvement of Liver Fibrosis in Patients Achieving a Sustained Virological Response to DAA Treatment for Hepatitis C” |
| Dr. Ayumi Sugiura (Japan) | ||
| P-07 | #10048 | “microRNA-6126 Reduces the Stability of NTCP Messenger RNA and Suppresses its Expression in Hepatocytes” |
| Dr. Koji Fujita (Japan) | ||
| P-08 | #10017 | “Molecular Characterization of Hepatitis B Virus in Young People of Vietnam” |
| Dr. Evgennia V. Lichnaia (Russia) | ||
| P-09 | #10043 | “Emergence of Novel Resistance-associated Substitutions against Pibrentasvir in Genotype 1b HCV-Infected Mice” |
| Dr. Takuro Uchida (Japan) | ||
| P-10 | #10023 | “B-cell Activating Factor Promotes Lipid Synthesis in Murine Hepatocytes” |
| Dr. Masanori Abe (Japan) | ||
| P-11 | #10026 | “Development of Human Hepatic Stellate Cell Activation/Deactivation Culture Condition Aiming the Liver Fibrosis Evaluation” |
| Dr. Seiichi Ishida (Japan) | ||
| P-12 | #10025 | “Ezetimibe Suppresses the Progression of NASH and NASH-associated HCC” |
| Dr. Kouichi Miura (Japan) | ||
| P-13 | #10038 | “Analysis of Liver Fibrosis Progression, Lipid Profile, and Atherosclerosis in NAFLD” |
| Dr. Shun-ichi Wakabayashi (Japan) | ||
| P-14 | #10030 | “Glycine Ameliorates Steatohepatitis via Reduction of Oxidative Stress in Hepatocyte- specific PTEN-deficient Mice” |
| Dr. Kazuyoshi Kon (Japan) | ||
| P-15 | #10015 | “Synergistic Regulation of Hepatic Fsp27b Expression by HNF4α and CREBH” |
| Dr. Ichiro C. Kasano-Camones (Japan) | ||
| P-16 | #10040 | “A Novel Isolation Method of Hepatic Stellate Cells from Tumor Tissue of Obesity-associated Hepatocellular Carcinoma” |
| Dr. Yi Cheng (China) | ||
| P-17 | #10036 | “Type IV Collagen 7S is the Most Accurate test for Identifying Advanced Fibrosis in Non- Alcoholic Fatty Liver Disease with Type 2 Diabetes” |
| Dr. Hiroshi Ishiba (Japan) | ||
| P-18 | #10055 | “Systemic Inflammation Predict 30-day Bacterial Infection Post-liver Transplantation” |
| Dr. Jiong Yu (China) | ||
| P-19 | #10021 | “Elevated Alpha Fetoprotein in the Absence of Hepatic Malignancy in a Patient with Acute Hepatitis” |
| Dr. Jacklyn M So-Cabahug (Philippines) | ||
| P-20 | #10005 | “Nanoparticle-mediated Delivery of 2-deoxy-D-glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice” |
| Dr. Sohji Nishina (Japan) | ||
| P-21 | #10033 | “The Complication Rate and Clinical Significance of Extrahepatic Autoimmune Diseases (EHAIDs) in Primary Biliary Cholangitis (PBC)” |
| Dr. Yuki Yamashita (Japan) | ||
| P-22 | #10058 | “Role of CD40 in Hepatocellular Carcinoma” |
| Dr. Vinh Hanh Ngo (Japan) | ||
| P-23 | #10049 | “Changes of Soluble Immune Checkpoint Proteins following Antiviral Treatment in Chronic Hepatitis C Patients and the Roles of the CD27-CD70 Pathway in Hepatocellular Carcinoma Development” |
| Dr. Minh Phuong Dong (Japan) | ||
| P-24 | #10012 | “Case Report of Overlap Syndrome: Autoimmune Hepatitis and Primary Biliary Cholangitis, a Vietnamese Patient Diagnosing by Pathology” |
| Dr. Lieu Quang Dau (Viet Nam) | ||
| P-25 | #10051 | “Functional Analysis of Liver Cirrhosis-associated Gut Microbiota Uncovers a Unique Mechanism of Hyperammonemia in Hepatic Encephalopathy” |
| Dr. Tomonori Kamiya (Japan) | ||
| P-26 | #10035 | “Role of the FibroScan-aspartate Aminotransferase Score in Risk Stratification for a Japanese Cohort with Fatty Liver Diseases” |
| Dr. Hideki Fujii (Japan) | ||
| P-27 | #10039 | “Possible Involvement of ZNF641 with the Prognosis of Hepatocellular Carcinoma” |
| Dr. Hirayuki Enomoto (Japan) | ||
| P-28 | #10004 | “The Long Non-coding RNA of RMRP is Repressed by PERK and Induces Apoptosis in Hepatocellular Carcinoma” |
| Dr. Atsushi Yukimoto (Japan) | ||
| P-29 | #10011 | “Identifying UGT1A1 Gene Mutations in Vietnamese Patients with Gilbert Syndrome” |
| Dr. Lieu Quang Dau (Viet Nam) | ||
| P-30 | #10020 | “Validation of Platelets - Albumin - Bilirubin (PALBI) Score for Predicting Overall Survival of Hepatocellular Carcinoma at Hanoi Medical University Hospital, Vietnam” |
| Dr. Bich Hang Doan (Viet Nam) | ||
| P-31 | #10016 | “Validation of ABCR and ART for Predicting Overall Survival in Patient with Hepato-cellular Carcinoma Treated with Transarterial Chemoembolism in Hanoi Medical University Hospital, Vietnam” |
| Dr. Duc Minh Pham (Viet Nam) | ||
| P-32 | #10024 | “A Novel Anticancer Therapy with Deferoxamine and Drugs Targeting Iron-chelation- Modulated Metabolism” |
| Dr. Koichi Fujisawa (Japan) | ||
| P-33 | #10059 | “Identification of Key Modules and Hub Genes Involved in Cholangiocarcinoma Progression and Prognosis” |
| Dr. Qigu Yao (China) | ||
| P-34 | #10031 | “PD-L1 Promotes Cell Proliferation in Liver Cancer Cells” |
| Dr. Toshimitsu Tanaka (Japan) | ||
| P-35 | #10003 | “Efficacy of Zinc Acetate in HCC Cell Lines via the Induction of Apoptosis” |
| Dr. Takashi Himoto(Japan) | ||
| P-36 | #10007 | “Liver Piopsy Technique in the Era of Cancer Genomic Therapies: A Single Center Retrospective Analysis” |
| Dr. Naoya Kanogawa (Japan) | ||
| P-37 | #10041 | “Intracellular Gaps Formation of Liver Sinusoidal Endothelial Cells Facilitates Cancer Cell Engraftment in Liver” |
| Dr. Truong Huu Hoang (Japan) | ||
| P-38 | #10045 | “Role of SKI in the Suppression of Cholangiocarcinoma Cell Proliferation by Inducing G1- phase Arrest: Validation of Results from Clinical Specimens” |
| Dr. Etsushi Kawamura (Japan) | ||
| P-39 | #10034 | “The Association between Plasma Free Amino Acids and Sarcopenia in the Course of Hepatocellular Carcinoma Recurrence” |
| Dr. Shunichi Tsuge (Japan) | ||
| P-40 | #10010 | “A Survey on Approaches towards Patients with Elevated Liver Enzymes before Surgery in Different Vietnamese Hospitals” |
| Dr. Hang Dao (Viet Nam) |
